Lyell Immunopharma, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Lyell Immunopharma, Inc. | LYEL - NASDAQ |
$16.00-$18.00 | $17.00 | $18.75 | 25 million | 6/17/2021 |
| Goldman Sachs, BofA Securities, JP Morgan, Morgan Stanley | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-05-25 Terms Added 2021-06-09 | ||||||
Lyell Immunopharma, Inc. Quote & Chart - Click for current quote - LYEL
IPO Boutique aggregates information on public companies and private companies, such as "LYEL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Lyell Immunopharma, Inc. (adapted from Lyell Immunopharma, Inc. prospectus):
They are a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "LYEL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.